It has been studied for use by rectal administration in the treatment of prostate cancer in men as well. The medication was introduced in the U.S. in 1947 by Schering as Synestrol and in France in 1948 as Cycladiene.
This drug has been studied for use via rectal administration to treat prostate cancer in men, and it was first marketed in the United States in 1947 under the name Synestrol by Schering, and later in France in 1948 as Cycladiene.